The Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Division of Diabetes Translation (DDT), Epidemiology and Statistics Branch (ESB) intends to award a sole source firm-fixed price services contract to the Regents of the University of Michigan. The address is 503 Thompson Street; Ann Arbor, Michigan 48109-1340. This contract will be for 12-months from time of award. The statutory authority for this sole source acquisition is 10 U.S.C. 2304 (c)(1) in accordance with FAR Part 13.106-1(b)(1) - Only one responsible source is reasonably available to satisfy the agency requirement. The NAICS Code for this procurement is 611310 (Colleges, Universities and Professional Schools). The size standard is $27.5 Million dollars. The Government intends to purchase research and development services to use Electronic Health Information (EHI) to estimate trends in macro vascular, micro vascular and acute complications among individuals with diagnosed diabetes. Diabetes mellitus is one of the most common chronic diseases in the United States with over 30 million people having the disease. It is also one of the costliest chronic diseases with direct costs of $245 billion in 2012 (CDC National Diabetes Statistics Report). Individuals with diabetes are at an increased risk of acute and chronic complications such as macro vascular and micro vascular complications. Assessing trends of these complications helps to determine the on-going risk to the population with diabetes and to assess the effectiveness of diabetes public health efforts, diabetes care and risk factor control. Recent reviews on trends in diabetes complications highlighted the importance of surveillance to track complications in light of increased prevalence of diabetes along with declining mortality. In the United States, there is evidence that diabetes related complications from cardiovascular disease (CVD) and end stage renal disease may be decreasing. However, other complications such as diabetic ketoacidosis (DKA) and lower extremity amputations (LEA) appear to be increasing. Current surveillance efforts for diabetic complications in the United States related to tracking and monitoring diabetic macro vascular, micro vascular and acute complications rely on a variety of data sources, including national surveys of individuals, national in-patient hospital surveys, hospital claims data, hospitalizations and emergency department visits. An additional potential resource for surveillance is the use of electronic health information. Electronic health information (EHI) may present a unique opportunity for creating an additional surveillance system for diabetic complications. Individuals with diabetes are likely to have encounters with the health care system related to diabetes. EHI-based surveillance systems could provide low-cost, efficient and timely disease surveillance from large and diverse populations to assess the incidence, prevalence and temporal trends. EHI data can contain demographics, physician billing claims, hospitalization and medication data, and have the advantages of cost effective, easy access and availability of longitudinal health information. The objectives of this project are to assess trends of acute and chronic complications of diabetes: 1) Among individuals with prevalent diabetes-Trends of macro -vascular complications (cardiovascular diseases (CVD), lower extremity amputations (LEA) micro-vascular complications (kidney disease and retinopathy), and acute complications (diabetic ketoacidosis (DKA), and severe hypoglycemia); and, 2) Trends of DKA at diagnosis among new cases of diabetes. The University of Michigan is working on a project that assesses trends in the incidence of both type 1 and type 2 diabetes. In this project, individuals are identified with incident and prevalent diabetes. The analysis can now be expanded to examine the trends of DKA at the time of diabetes diagnosis among individuals with type 1 or type 2 diabetes, overall and by demographic factors and region in the United States. In addition, individuals are identified with prevalent diabetes that will be used to assess chronic complications, including CVD, LEA and acute complications including DKA. The advantage of using this data source to examine trends in complications allows the University to look at both incident and prevalent cases of diabetes, by type of diabetes, and the association with co-morbidities, medications, and health care utilization. The University of Michigan is uniquely able to meet the objectives for this contract based on previous work and experience. Currently, researchers at the University of Michigan are completing a contract with the CDC using a large electronic health information database to assess the incidence of type 1 and type 2 diabetes in the United States overall, by age, sex, race / ethnicity and state. The researchers at the University of Michigan already have access to the data, developed methods to identify diabetes cases and can rapidly implement the analyses needed to achieve the project objectives. There is no logical entity to hand this procurement off to build upon this work. The University of Michigan has a strong history of using large electronic health information databases for epidemiological research and surveillance. Given the relatively short timeline of one year (12 months) for the project period, this experience is beneficial. No solicitation will be posted to FedBizOpps. We will only issue a solicitation to the Regents of the University of Michigan. The Regents of the University of Michigan is the only source that is capable of meeting all of the CDC's technical requirements for this procurement. This notice of intent is not a request for proposal. A determination to compete this procurement based on response to this notice is solely within the discretion of the Contracting Officer. Interested parties who believe they possess the capability to satisfy this requirement should submit a capability statement demonstrating their ability to meet this requirement. All responses must be sent in writing to Mr. Tim Williams via email to TLWilliams3@cdc.gov using solicitation number 75D301-19-Q-71011 in the subject line, no later than 7:00am Eastern Time, September 6, 2019.
